Audentes Therapeutics (BOLD) PT Raised to $50 at Chardan Capital Markets
Tweet Send to a Friend
Chardan Capital Markets analyst Gbola Amusa raised the price target on Audentes Therapeutics (NASDAQ: BOLD) to $50.00 (from $40.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
